Osteoporosis: The Silent Killer
A systemic skeletal disease characterized by low bone mass and deterioration of bone tissue, osteoporosis, or low bone mineral density currently affects more than 28 million Americans and an even greater number of Europeans. The disease is especially prevalent among women of Northern European descent, although all ethnic groups and sexes are affected. It is estimated that among women of Northern European descent that nearly 80% will suffer from loss of bone density. Among men of Northern European descent the number is estimated at 33%. Osteoporosis leads to bone fractures that may result in infection and death. It is estimated in the United States alone that over $14 billion in medical costs are directly related to treating osteoporosis. The loss in human and economic terms is incalculable, often leading to incapacitation and confinement in a nursing home for many sufferers.

Prevention
Osteoporosis can be prevented and controlled by proper diet, exercise and the regular consumption of calcium supplements. In women, it has been shown that the use of natural progesterone cream will not only prevent osteoporosis in women but will restore bone loss. However, progesterone is ineffective for men and many women may want additional protection, especially if their diet, life style and genetic background make the development of osteoporosis likely.

While prevention is obviously the most effective approach to this potentially life-threatening disease, scientists have discovered that 7-isopropoxy isoflavone, or ipriflavone, may help those who have already experienced a loss of bone density. A synthetic isoflavone derivative, ipriflavone functions primarily to suppress bone resorption. But in vitro studies have also shown its potential in stimulating bone cell growth.

Although the discovery of ipriflavone dates back to the 1930s, it has not been generally available, as it is a natural substance that cannot be patented resulting in lack of interest by the pharmaceutical industry. First produced in the laboratory in 1970, ipriflavone's calcium retaining effects prompted scientists to further experiment with bone diseases related to bone mass loss. Animal studies, which began in 1974, soon gave way to human studies in 1981. By the 1980s, a number of prospective, randomized, double-blind, placebo controlled studies demonstrated that ipriflavone had a preventive effect on decreased bone mass in postmenopausal women.

Researchers further noted that while ipriflavone shares structural similarities with naturally occurring estrogens, it does not exert estrogenic effects in the hypothalamus and pituitary gland. Ipriflavone simply improves the properties of bone tissue and prevents the loss of bone mass in patients treated with estrogens.

Strictly Controlled Human Tests Prove Ipriflavone Works
In 1992, researchers at the International Journal of Bone, Mineral and Calcium Regulation Research presented evidence that a daily dose of 600 mg of ipriflavone increased bone density by as much as 9% in three to nine months. This evidence was further supported in 1994 by two studies that demonstrated a significant reduction in vertebral fractures in human patients after a two-year treatment with ipriflavone. Since then, more than 400 patients treated with ipriflavone in double-blind, placebo controlled studies have noted significant increments of .5 to 7.1 percent in total body, forearm and vertebral bone mineral density. Many of these patients have risen from their beds and walkers and assumed an active life.

How Ipriflavone Works
Ipriflavone is rapidly absorbed through the small intestine, particularly when taken with food, and then is metabolized by cells, primarily in the liver. The ingredient is then excreted in the urine in less than 10 hours. When compared with Calcitonin, one of the most popularly prescribed prescription drugs, ipriflavone proved a greater ability to inhibit the formation osteoclasts (old bone cells) and bone resorption, while simultaneously stimulating the formation of osteoblasts, or new bone cells. Unlike the prescription drug, there are no side effects.

What to Do?
All women and most men in the high-risk category should supplement their diet with Ipriflavone to help maintain normal levels of bone density. Ipriflavone, proper diet, and calcium supplementation promise to eliminate osteoporosis as one of the top three most life threatening diseases in the United States, Canada, Europe, and Australia.

For those already afflicted with bone mass loss ipriflavone is a necessity to maintain or resume an active life and to lessen the risk of incapacitating, life-threatening fracture. Ipriflavone, exercise, diet will boost bone density back to a healthy level.

ORDER IPRIFLAVONE TODAY. 600 mg per day is required to both prevent and restore bone loss. We recommend Ipriflvone be taken together with calcium citrate or our new Hydroxyappetite Formula.

Brand
Supplementspot.